Fig. 4.

Cytotoxicity of 5T4_p17-specific TCR-transduced CD8⁺ T-cells against 5T4-expressing tumor targets. CD8⁺ T-cells expressing 5T4_17–25-specific TCRs were tested for recognition of tumor target lines in a 4-h cytotoxicity assay with 10:1 E:T. For each target cell-line, 5T4_17–25-specific TCR transduced effector CD8⁺ T-cells were plotted in the following order: HD_A-2, HD_A-15, HD_B-19, HD_B-21, HD_C-3, HD_C-17, KCD_D-6, and untransduced. a Targets are 5T4⁺/HLA-A2⁺ RCC cell lines (A498, BB65, TREP, DOBSKI; red bars), the 5T4⁺/HLA-A2⁻ RCC line (SST548; open bars) and the 5T4⁻/HLA-A2⁺ LCL (BB65-LCL; gray shading). b Targets are 5T4⁺/HLA-A2⁺ breast cancer line (MDA231; blue bars), a 5T4⁺/HLA-A2⁻ breast cancer line (BT20; open bars) and 5T4⁺/HLA-A2⁺ colon cancer line (SW480, green bars). CD8⁺ T-cells with (gTRAC_KO) or without (gCtrl) native TRA disruption expressing 5T4 _p17-specific TCRs were tested for recognition of c 5T4⁺/HLA-A2⁺ RCC cell-lines (A498, BB65, DOBSKI), the 5T4⁺/HLA-A2⁻ RCC line (SST548), the 5T4⁻/HLA-A2⁺ BB65-LCL, and d paired primary 5T4⁺/HLA-A2⁺ RCC and autologous PTEC cell-lines from four RCC patients